Analyst Conference Summaries |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Sage Therapeutics
|
2024 | |||
Sage Therapeutics Q1 2024 |
Sage Therapeutics Q2 2024 |
Sage Therapeutics Q3 2024 |
|
April 25, 2024 | July 31, 2024 | Oct. 29, 2024 | |
2023 | |||
Sage Therapeutics Q1 2023 |
Sage Therapeutics Q2 2023 |
Sage Therapeutics Q3 2023 |
Sage Therapeutics Q4 2023 |
May 2, 2023 | Aug. 7, 2023 | Nov. 7, 2023 | Feb. 14, 2024 |
2022 | |||
Sage Therapeutics Q1 2022 |
Sage Therapeutics Q2 2022 |
Sage Therapeutics Q3 2022 |
Sage Therapeutics Q4 2022 |
May 3, 2022 | Aug. 2, 2022 | Nov. 8, 2022 | Feb. 16, 2023 |
2021 | |||
Sage Therapeutics Q1 2021 |
Sage Therapeutics Q2 2021 |
Sage Therapeutics Q3 2021 |
Sage Therapeutics Q4 2021 |
May 4, 2021 | Aug. 3, 2021 | Nov. 2, 2021 | Feb. 24, 2022 |
2020 | |||
Sage Therapeutics Q3 2020 |
Sage Therapeutics Q4 2020 |
||
Nov. 5, 2020 | Feb. 24, 2021 |
Sage Therapeutics (SAGE) is a commercial stage biotechnology company specializing in therapies for brain disorders.
More Analyst Conference Pages:
AGEN |
AGIO |
ALLO |
ALNY |
AMAT |
AMGN |
ARWR |
APRE |
BIIB |
BLRX |
BLUE |
BMY |
CDTX |
CLDX |
FATE |
GILD |
GLYC |
ILMN |
INO |
IONS |
MCHP |
MRNA |
PLX |
REGN |
RNA |
SANA |
SAGE |
SYRS |
TSVT |
VRTX |
VSTM |
WBA |
Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.
Copyright 2024 William P. Meyers